Clinical Trials Logo

Filter by:
NCT ID: NCT04480619 Not yet recruiting - Clinical trials for Angiogenic Breast Cancer

Safety and Efficacy of Ga68 Αvβ3 IAC PET/CT for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients

Shiva
Start date: August 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/IIa, open label, multicenter interventional study of Gallium-68 radiolabeled PEG-αvβ3-Integrin Adhesion Complex antagonist conjugate (Ga-68-PEG-Αvβ3-IAC) Positron Emission Tomography (PET/CT) imaging, intended for diagnosis, and clinical management of patients with angiogenic breast cancer.

NCT ID: NCT04474262 Not yet recruiting - Clinical trials for Acute-On-Chronic Liver Failure

Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.

Start date: July 15, 2020
Phase: N/A
Study type: Interventional

The patients with ACLF having Ascites who require ascitic tapping will undergone ascitic tapeither under albumin cover alone or with midodrine. The patient will be monitored for complication and changes of PICD. Study analysis will be done with primary objective being reduction in incidence of PICD.

NCT ID: NCT04469127 Not yet recruiting - Clinical trials for Breast Cancer Stage IV

A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.

Heroine01
Start date: September 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a Phase I/II clinical evaluation of a new investigational agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to treat patients with unresectable angiogenic breast cancer who have previously been treated with at least one prior line of therapy.

NCT ID: NCT04433273 Not yet recruiting - Clinical trials for Overweight and Obesity

Electrical Vestibular Stimulation (VeNS): Assessment of AMPK & SIRT1 Following Repeated Usage

Start date: May 2024
Phase: N/A
Study type: Interventional

The vestibular system which is responsible for balance and equilibrium constitutes our sixth sense. Metabolic Syndrome is a constellation of metabolic abnormalities characterized by obesity, insulin resistance (diabetes mellitus), hypertension, and dyslipidemia. It is generally agreed that a combination of three or more of the following components must be present: large waist circumference, elevated triglyceride, decreased high-density lipoprotein (HDL) cholesterol raised blood pressure, and elevated fasting blood sugar (FBS). Sirtuin 1 (SIRT1) is one of seven mammalian orthologs of the yeast protein silent information regulator. It is a conserved NAD-dependent protein deacetylase that decreases in cells that have high insulin resistance. In vivo, insulin resistance and metabolic syndrome were associated with low SIRT1 gene and protein expression. SIRT1 plays an important role to stimulate AMPK in improving mitochondrial function both in-vitro and in-vivo. Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) is a key factor in regulating energy metabolism, placing it at the center stage in studies of diabetes and related metabolic disorders like metabolic syndrome. It was reported that over a period of 6 weeks regular vestibular rehabilitation exercises caused an increase in the expression of SIRT1. The sleep inducing effects of vestibular stimulation is well known. Earlier studies reported improvement in the scores of Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) followed by the vestibular stimulation. Hence, we hypothesize that vestibular stimulation will lead to up-regulation of both SIRT1 and AMPK.

NCT ID: NCT04422379 Not yet recruiting - COVID-19 Clinical Trials

COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study

Start date: June 7, 2020
Phase:
Study type: Observational

COVID-19 and liver injury in patients with or without underlying liver disease: A multi-centre retrospective-prospective observational study. All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 & prospective data from approval till 30/6/2020), will be included

NCT ID: NCT04420780 Not yet recruiting - Caries Clinical Trials

Effect of the Use of Xylitol Gum in the Prevention of Caries Lesions in Children Living in Ladakh

CaPreXCh
Start date: August 2021
Phase: N/A
Study type: Interventional

Background: Ladakh is a region administered by India, covering an area slightly larger than Croatia; it is part of the larger region of Kashmir and Jammu. Till now, oral health data on population living in Ladakh are not available. The aim of the present preventive project will be to record the caries prevalence of schoolchildren living in Ladakh and to implement a school-based xylitol program using chewing gums in order to reduce caries incidence. Methods: The protocol of the Caries Prevention Xylitol in Children (CaPreXCh) trial is designed as a triple-blind randomized, controlled, parallel-group clinical trial in children aged 5-14 years. The study will be carried out from August 2021 to August 2024 in Zanskar Valley (Ladakh). Participants will be randomly allocated into two groups: subjects who will receive a 100% xylitol chewing gum, and those who will receive a 22% xylitol gum. The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon) for one school-year. Clinical examination will comprise an oral examination: caries index (ICDAS scores), bleeding on probing recording and evaluation of plaque pH fluctuation after sucrose challenge and will be performed at baseline (t0) and repeated 12 months at the end of the chewing-gum administration period (t1) as interim examination, after 12 months (t2) and 24 months (t3) after the end of the experimental period (chewing gum use). The primary outcome will be the caries increment measured both at enamel and dentinal level. Data analysis will be conducted through Kaplan-Meyer graphs to evaluate caries increment as primary outcome, and the methods will be compared to each other with Cox regression with shared frailty. The net caries increment for initial, moderate and severe caries level, using ICDAS (Δ-initial, Δ-moderate and Δ-severe), will be calculated. Discussion: This is the first clinical trial to assess the effect of chewing gum containing only xylitol as sweeteners for caries prevention. Moreover, the children object of this study is a population with special living conditions.

NCT ID: NCT04335227 Not yet recruiting - Clinical trials for Polycystic Ovary Syndrome

Yoga Therapy and Aerobic Exercise on Anti-Mullerian Hormone in Young Women With Polycystic Ovary Syndrome

Start date: November 14, 2021
Phase: N/A
Study type: Interventional

Weight loss and lifestyle modifications are much required in women with Polycystic ovarian syndrome (PCOS). Yoga has gained great importance as an alternate medicine in recent years which is helpful in lifestyle modifications. Weight loss can be achieved by regular aerobic activity. In recent years, excessive production of anti-mullerian hormone (AMH) has been considered as the etiology of PCOS. AMH is also emerging as a diagnostic and screening tool for PCOS. Effect of yoga therapy on adolescent girls have proved to be effective. But, researches on young women undergoing yoga therapy and combined effect of aerobic exercise and yoga therapy are still lacking. Hence, the investigators aimed t o establish the benefits of yoga therapy and aerobic exercise on Anti-Mullerian Hormone and other biochemical markers in young women with polycystic ovary syndrome.

NCT ID: NCT04302402 Not yet recruiting - Dyspepsia Clinical Trials

Multi-dimensional Clinical and Pathophysiological Profiles of Patients With Functional Dyspepsia and Effect of Gut Microbiota Manipulation Using Rifaximin for Its Treatment

Start date: March 2020
Phase: Phase 2
Study type: Interventional

Functional dyspepsia (FD) is a common condition associated with significant morbidity, healthcare expenditure, work absenteeism and productivity, and reduced quality of life. The prevalence of this condition is as high as 15% in the rural (Jaunpur district, Uttar Pradesh) and 30% of the urban (Mumbai) Indian population. Pathophysiologically, FD is an enigmatic condition that may be contributed by a variable combination of psychosocial issues like anxiety, depression, insomnia, and micro-organic issues like Helicobacter pylori infection, gastritis, duodenitis, hypersecretion of acid, degree of gastric atrophy, gastric microbiota dysbiosis. Accordingly, investigators want to study these factors among patients with FD. Rifaximin has been shown to be useful in the treatment of FD in a recent randomized controlled trial from Hong Kong. Since microbiota dysbiosis may be an important issue in FD, investigators want to treat them with rifaximin in a randomized placebo-controlled trial and repeat the parameters such as dyspepsia score, hospital Anxiety and Depression Scale (HADS) score, Pittsburgh Sleep Quality Index (PSQI). Investigators wish to study the pathogenetic mechanism of FD and evaluate baseline factors that may help to predict response to gut microbiota manipulation in these patients. Objectives: a. To study the patients with FD for gut microbiota including gastric H. pylori, gastric atrophy (by PG-1 PG-II ratio), hospital anxiety and depression score, and sleep disorders b. To see the effect of treatment of these patients with rifaximin vs. placebo in a randomized controlled trial not only for the improvement in symptoms but also for improvement in HADS score and sleep quality c. To study whether any pre-treatment factors including gut microbiota predict the response of symptoms to treatment with rifaximin.

NCT ID: NCT04203355 Not yet recruiting - Infertility Clinical Trials

Multi-country, Multi-center Cohort Study of Anti-Mullerian Hormone Profile in Asia Pacific Infertile Patients

Start date: January 1, 2020
Phase:
Study type: Observational

This study is to detect the infertile couple (women) Anti-Mullerian Hormone (AMH) profile in major subgroups such as Poly Cystic Ovarian Syndrome (PCOS), Endometriosis, etc via age intervals and ethnic difference.

NCT ID: NCT04142398 Not yet recruiting - HIV Infection Clinical Trials

Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men

Start date: April 30, 2025
Phase:
Study type: Observational

This research trial studies the incidence of human papilloma virus (HPV) infection and HPV-associated disease in screening Indian men who have sex with human immunodeficiency virus (HIV)-positive men. Gathering health information over time from Indian men who have sex with men (MSM) may help doctors determine how many HIV -positive MSM develop new HPV infections and how many HIV-positive MSM have HPV related disease.